Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of BMS-986177 after acute ischemic stroke or transient ischemic attack
2017-005029-19Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of milvexian in ischemic stroke and transient ischaemic attack (TIA) (3 arms), sponsored by Bristol Myers Squibb. Started Oct 2018; status: completed.
02
Drugs
milvexian
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on 2017-005029-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005029-19.